D. Boral Capital Maintains Buy on Trevi Therapeutics, Maintains $19 Price Target
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
D. Boral Capital analyst Jason Kolbert maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $19 price target.
D. Boral Capital analyst Jason Kolbert maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $19 price target.